Conventional allograft and autograft in low grade lymphoma

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 1 SPEC. ISS., 2005, Pages 113-128

  Avivi, Irit ^a   Goldstone, Anthony H ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b UCH   (United Kingdom)

Author keywords

Allograft; Autograft; Lymphoma

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IODINE 131; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER GRADING; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DONOR; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MANTLE CELL LYMPHOMA; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 13344286291     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.017     Document Type: Review

References (78)

1. K. Van Besien F.R. Loberiza Jr R. Bajorunaite et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma Blood 102 2003 3521-3529
2. P.J. Bierman J.W. Sweetenham F.R. Loberiza Jr Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation Journal of Clinical Oncology 21 2003 3744-3753
3. H.C. Schouten S. Kvaloy M. Sydes et al. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL) Annals of Oncology 11 supplement 1 2000 91-94
4. H.C. Schouten W. Qianm S. Kvaloym et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial Journal of Clinical Oncology 21 2003 3918-3927
5. Y.J. Liu D.Y. Mason G.D. Johnson et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis European Journal of Immunology 21 1991 1905-1910
6. D.T. Chao & S.J. Korsmeyer BCL-2 family: Regulators of cell death Annual Review in Immunology 1998 395-419 [Review]
7. S. Galimberti F. Guerrini F. Morabito et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: Efficacy of in vivo purging by Rituximab Bone Marrow Transplantation 32 2003 57-63
8. K.E. Summers L.K. Goff A.G. Wilson et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease in patients with follicular lymphoma Journal of Clinical Oncology 19 2001 420-424
9. P. Colombat G. Salles N. Brousse et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumour burden: Clinical and molecular evaluation Blood 97 2001 101-106
10. A. Lopez-Guillermo F. Cabanillas P. McLaughlin et al. The clinical significance of molecular response in indolent follicular lymphomas Blood 91 1998 2955-2960
11. N.L. Berinstein R. Buckstein K. Imrie et al. Bcl-2 clearance: Optimising outcomes in follicular non-Hodgkin's lymphoma Bone Marrow Transplantation 29 supplement 1 2002 S14-S17
12. A.S. Freedman D. Neuberg P. Mauch et al. ong-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 94 1999 3325-3333
13. J.G. Gribben A.S. Freedman D. Neuberg et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New England Journal of Medicine 325 1991 1525-1533
14. C. Tarella P. Corradini M. Astolfi et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions Leukemia 13 1999 1456-1462
15. M. Ladetto P. Corradini S. Vallet et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) Blood 100 2002 1559-1565
16. M.K. Brenner D.R. Rill R.C. Moen et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 341 1993 85-86
17. D.R. Rill V.M. Santana W.M. Roberts et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells Blood 84 1994 380-383
18. M. Magni M. Di Nicola L. Devizzi et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion Blood 96 2000 864-869
19. B. Seyfarth R. Kuse R. Sonnen et al. Autologous stem cell transplantation for follicular lymphoma: No benefit for early transplant? Annals of Hematology 80 2001 398-405
20. S.J. Horning R.S. Negrin R.T. Hoppe et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial Blood 97 2001 404-409
21. A.R. Perry M.J. Watts A.J. Peniket et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy Bone Marrow Transplantation 21 1998 1201-1205
22. J.F. Seymour A.P. Grigg J. Szer & R.M. Fox Fludarabine and mitoxantrone: Effective and well tolerated salvage therapy in relapsed indolent lymphoproliferative disorders Annals of Oncology 12 2001 1455-1460
23. D. Laszlo P. Galieni D. Raspadori et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin lymphoma patients Leukemia and Lymphoma 37 2000 157-161
24. J.O. Armitage P.P. Carbone J.M. Connors et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients Journal of Clinical Oncology 21 2003 897-906 [Review]
25. M. Del Canizo M. Amigo J.M. Hernandez et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation Haematologica 85 2000 403-409
26. C. Hosing M. Munsell S. Yazji et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma Annals of Oncology 13 2002 450-459
27. C. Metayer R.E. Curtis J. Vose et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study Blood 101 2003 2015-2023
28. I.N. Micallef D.M. Lillington J. Apostolidis et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies Journal of Clinical Oncology 8 2000 947-955
29. A. Krishnan S. Bhatia M.L. Slovak et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors Blood 95 2000 1588-1593
30. D.W. Milligan M.C. Ruiz De Elvira H.J. Kolb et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation British Journal of Haematology 106 1999 1020-1026
31. J. Sevilla A. Rodriguez D. Hernandez-Maraver et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation Annals of Hematology 81 2002 11-15
32. R.A. Clynes T.L. Towers L.G. Presta J.V. Ravetch et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumour targets Nature Medicine 6 2000 443-446
33. G. Cartron L. Dacheux G. Salles et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754-758
34. J.C. Byrd S. Kitada I.W. Flinn et al. The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukaemia: Evidence of caspase activation and apoptosis induction Blood 99 2002 1038-1043
35. P. McLaughlin A.J. Grillo-Lopez B.K. Link et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program Journal of Clinical Oncology 16 1998 2825-2833
36. T.A. Davis C.A. White A.J. Grillo-López et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab Journal of Clinical Oncology 17 1999 1851-1857
37. A. Lopez C. Palacios G. Perez-Manga et al. Final results of a phase II study to evaluate the efficacy and safety of treatment and retreatment with rituximab in relapsed follicular or low-grade NHL Blood 98 2001 605a [Abstract 2531].
38. M.S. Czuczman A.J. Grillo-Lopez C.A. White et al. Progression-free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab/CHOP immunochemotherapy Blood 98 2001 601a [Abstract 2519].
39. M.S. Csuczman A. Fallon A. Mohr et al. Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): Final report Blood 98 2001 601a [Abstract 2518].
40. O.W. Press J.F. Eary F.R. Appelbaum et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support New England Journal of Medicine 329 1993 1219-1224
41. O.W. Press J.F. Eary T. Gooley et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 96 2000 2934-2942
42. A.K. Gopal T.A. Gooley D.G. Maloney et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis Blood 102 2003 2351-2357
43. A.S. Freedman D. Neuberg J.G. Gribben et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission Journal of Clinical Oncology 16 1998 13-18
44. R. Buckstein K. Imrie D. Spaner et al. Stem cell function and engraftment is not affected by in vivo purging with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Seminars in Oncology 26 supplement 14 1999 115-122
45. M.E. Reff K. Carner K.S. Chambers et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435-445
46. S.M. Horwitz R.S. Negrin K.E. Stockerl-Goldstein et al. Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas Blood 98 2001 862a [Abstract 3578].
47. M.T. Voso G. Pantel M. Weis et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma British Journal of Haematology 109 2000 729-735
48. F. Berger P. Felman A. Sonet et al. Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome Blood 83 1994 2829-2835
49. E. Zucca S. Fontana E. Roggero et al. Treatment and prognosis of centrocytic (mantle cell) lymphoma: A retrospective analysis of twenty-six patients treated in one institution Leukemia and Lymphoma 13 1994 105-110
50. D.A. Stewart J.M. Vose D.D. Weisenburger et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma Annals in Oncology 6 1995 263-266
51. R. Haas G. Brittinger P. Meusers et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma Leukemia 10 1996 1975-1979
52. A.M. Gianni M. Magni M. Martelli et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) Blood 102 2003 749-755
53. J. Mangel R. Buckstein K. Imrie et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma Seminars in Oncology 29 1 supplement 2 2002 56-69
54. J. Romaguera F. Cabanillas N.H. Dang et al. Mantle cell lymphoma (MCL)-high rates of complete remission (CR) and prolonged failure-free survival (FFS) with rituxan-hyper CVAD (R-HCVAD) without stem cell transplant (SCT) Blood 98 2001 726a [Abstract 3030].
55. T.E. Witzig I.W. Flinn L.I. Gordon et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma Journal of Clinical Oncology 20 2002 3262-3269
56. R.O. Dillman Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Current Hematology Reports 2 2003 30-37. [Review].
57. T.E. Witzig L.I. Gordon F. Cabanillas et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 20 2002 2453-2463
58. R.J. Jones R.F. Ambinder S. Piantadosi & G.W. Santos Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 1991 649-653
59. D.I. Marks R. Lush J. Cavenagh et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood 100 2002 3108-3114
60. C.L. Toze J.D. Shepherd J.M. Connors et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia Bone Marrow Transplantation 25 2000 605-612
61. K. van Besien K.A. Sobocinski P.A. Rowlings et al. Allogeneic bone marrow transplantation for low-grade lymphoma Blood 92 1998 1832-1836
62. I. Yakoub-Agha A. Fawaz O. Folliot et al. Allogeneic bone marrow transplantation in patients with follicular lymphoma: A single center study Bone Marrow Transplantation 30 2002 229-234
63. D.L. Forrest K. Thompson T.J. Nevill et al. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma Bone Marrow Transplantation 29 2002 973-978
64. I.F. Khouri M. Keating M. Korbling et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies Journal of Clinical Oncology 16 1998 2817-2824
65. C.M. Mandigers J.P. Meijerink J.M. Raemaekers et al. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) Lancet 352 1998 1522-1523
66. C.M. Mandigers L.F. Verdonck J.P. Meijerink et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation Bone Marrow Transplantation 32 2003 1159-1163
67. K.S. Peggs K. Thomson D.P. Hart et al. Dose escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses Blood 103 2004 1548-1556
68. V. Ratanatharathorn J. Uberti C. Karanes et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 84 1994 1050-1055
69. L.F. Verdonck A.W. Dekker H.M. Lokhorst et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 90 1997 4201-4205
70. L.F. Verdonck Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: Updated results of the Utrecht experience Leukemia and Lymphoma 34 1999 129-136
71. K. Izutsu Y. Kanda H. Ohno et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: A study from the Japan Marrow Donor Program Blood 103 2004 1955-1960
72. S.P. Robinson A.H. Goldstone S. Mackinnon et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 2002 4310-4316
73. A.Y. Ho S. Devereux G.J. Mufti et al. Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions Bone Marrow Transplantation 31 2003 551-557
74. E. Morris K. Thomson C. Craddock et al. Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL) Blood 100 2002 40a [Abstract 139].
75. C.I. Chen M. Crump R. Tsang et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma British Journal of Haematology 113 2001 202-208
76. J.M. Foran J. Apostolidis D. Papamichael et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre Annals of Oncology 9 1998 865-869
77. C.D. Williams C.N. Harrison T.A. Lister et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Lymphoma Working Party-European Bone Marrow Transplant Registry Journal of Clinical Oncology 19 2001 727-735
78. J. Rodriguez M.J. Keating S. O'Brien et al. Allogeneic haematopoietic transplantation for Richter's syndrome British Journal of Haematology 110 2000 897-899